METHODS article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1562481
This article is part of the Research TopicAdvances in targeted therapeutics for gastrointestinal cancersView all 4 articles
HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective Phase Ib/II trial
Provisionally accepted
- Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pancreatic tumors are highly lethal and a leading cause of cancer mortality. While systemic chemotherapy is the mainstay for advanced disease, its efficacy remains limited. KRAS mutations occur in approximately 88% of pancreatic ductal adenocarcinoma (PDAC), of which KRAS G12D comprises up to 39.5%.Despite the promise of KRAS G12D inhibitors, drug resistance persists. Combining KRAS and EGFR inhibitors has shown clinical efficacy in select solid tumors.To assess the safety and efficacy of HRS-4642 (KRAS G12D inhibitor) plus nimotuzumab (EGFR inhibitor) in patients harboring the KRAS G12D mutation, recurrent/metastatic PDAC refractory to standard systemic therapy.This is an open-label, single-center, exploratory clinical trial.Methods: This study will enroll patients with histologically or cytologically confirmed recurrent or metastatic PDAC harboring the KRAS G12D mutation, who have documented disease progression or intolerance to first-line systemic therapy. In Phase Ib, the safety profile of the investigational agent HRS-4642 will be assessed starting at an initial dose of 1200 mg administered every two weeks (Q2W). Dose reductions to 1000 mg Q2W or 800 mg Q2W will be implemented for dose-limiting toxicities. The recommended Phase II dose (RP2D) of HRS-4642 in combination with nimotuzumab (400 mg weekly, QW) will be determined based on safety and preliminary efficacy evaluation. Phase II will employ Simon's two-stage minimax design, with planned enrollment of approximately 20 participants. The primary endpoints for Phase Ib are safety profile characterization and RP2D determination; secondary endpoints include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DoR). For Phase II, the primary endpoint is ORR, with secondary endpoints comprising PFS, OS, DCR, safety, and DoR.: This exploratory clinical trial may yield critical safety/efficacy data supporting novel combination therapy for advanced PDAC. Its findings could advance the application paradigm of dual-target inhibition in pancreatic cancer therapeutics. Trial registration: This study was registered on ClinicalTrials.gov with NCT06773130. Ethics: This study protocol has been approved by the Ethics Committee of West China Hospital (2024(2239)).
Keywords: Pancreatic Ductal Adenocarcinoma, KRAS G12D mutation, HRS-4642, nimotuzumab, combination therapy
Received: 17 Jan 2025; Accepted: 24 Jun 2025.
Copyright: © 2025 Leng, Zhou, Wang, Xu, Zhang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dan Cao, Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.